Protocol for a cohort study to evaluate the effectiveness and cost-effectiveness of general population screening for cardiovascular disease: the Viborg Screening Programme (VISP)

Author:

Høgh AnnetteORCID,Lindholt Jes Sanddal,Søgaard Rikke,Refsgaard Jens,Svenstrup Dorte,Moeslund Niels-Jørgen,Bredsgaard Mette,Dahl MarieORCID

Abstract

Introduction The prevalence of cardiovascular disease (CVD) is increasing. Furthermore, asymptomatic individuals may not receive timely preventive initiatives to minimise the risk of further CVD events. Paradoxically, 80% of CVD events are preventable by early detection, followed by prophylactic initiatives. Consequently, we introduced the population-based Viborg Screening Programme (VISP) for subclinical and manifest CVD, focusing on commonly occurring, mainly asymptomatic conditions, followed by prophylactic initiatives. The aim of the VISP was to evaluate the health benefits, harms and cost-effectiveness of the VISP from a healthcare sector perspective. Furthermore, we explored the participants’ perspectives. Methods and analysis From August 2014 and currently ongoing, approximately 1100 men and women from the Viborg municipality, Denmark, are annually invited to screening for abdominal aortic aneurysm, peripheral arterial disease, carotid plaque, hypertension, diabetes mellitus and cardiac arrhythmia on their 67th birthday. A population from the surrounding municipalities without access to the VISP acts as a control. The VISP invitees and the controls are followed on the individual level by nationwide registries. The primary outcome is all-cause mortality, while costs, hospitalisations and deaths from CVD are the secondary endpoints. Interim evaluations of effectiveness and cost-effectiveness are planned every 5 years using propensity score matching followed by a Cox proportional hazards regression analysis by the ‘intention-to-treat’ principle. Furthermore, censoring-adjusted incremental costs, life-years and quality-adjusted life-years are estimated. Finally, the participants’ perspectives are explored by semistructured face-to-face interviews, with participant selection representing participants with both negative and positive screening results. Ethics and dissemination The VISP is not an interventional trial. Therefore, approval from a regional scientific ethical committee is not needed. Data collection from national registries was approved by the Regional Data Protection Agency (record no. 1-16-02-232-15). We ensure patient and public involvement in evaluating the acceptability of VISP by adopting an interviewing approach in the study. Trial registration number NCT03395509.

Funder

The foundation of Rosa og Asta Jensen, Viborg Regional Hospital, Denmark

The Health Resarch of Central Denmark

Publisher

BMJ

Subject

General Medicine

Reference41 articles.

1. European Society of Cardiology: cardiovascular disease statistics 2021

2. Cardiovascular disease in Europe: epidemiological update 2016

3. CVD statistics 2017 2017.

4. Eurostat . Population structure and ageing - statistics explained: eurostat (online data code:demo_pjanind). Available: https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Population_structure_and_ageing [Accessed 16 Feb 2022].

5. World Health Organization . Data and statistics. 2022. Available: https://www-euro-who-int.ez-vks.statsbiblioteket.dk:12048/en/health-topics/noncommunicable-diseases/cardiovascular-diseases/data-and-statistics [Accessed 16 Feb 2022].

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3